Betsy Laplant
Overview
Explore the profile of Betsy Laplant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kumar S, Buadi F, Laplant B, Halvorson A, Leung N, Kapoor P, et al.
Blood Cancer J
. 2018 Aug;
8(8):70.
PMID: 30061664
Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and...
12.
Larsen J, Shanafelt T, Leis J, Laplant B, Call T, Pettinger A, et al.
Am J Hematol
. 2017 Apr;
92(8):759-763.
PMID: 28402581
Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt...
13.
Johnston P, Laplant B, McPhail E, Habermann T, Inwards D, Micallef I, et al.
Lancet Haematol
. 2016 Jul;
3(7):e309-16.
PMID: 27374464
Background: The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus. Everolimus has activity in relapsed DLBCL....
14.
Crozier J, Advani P, Laplant B, Hobday T, Jaslowski A, Moreno-Aspitia A, et al.
Clin Breast Cancer
. 2015 Sep;
16(1):23-30.
PMID: 26381420
Background: Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially...
15.
Kumar S, Krishnan A, Laplant B, Laumann K, Roy V, Zimmerman T, et al.
Am J Hematol
. 2015 Sep;
90(12):1106-10.
PMID: 26331432
Bendamustine is a multifunctional alkylating agent with single agent activity in myeloma. We designed the current phase 1/2 trial to determine the maximum tolerated doses (MTD) of bendamustine that can...
16.
Witzig T, Reeder C, Han J, Laplant B, Stenson M, Tun H, et al.
Blood
. 2015 Apr;
126(3):328-35.
PMID: 25921059
Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity...
17.
Gustafson M, Lin Y, Laplant B, Liwski C, Maas M, League S, et al.
J Immunother Cancer
. 2014 Dec;
1:7.
PMID: 25512872
Background: We have developed a novel approach to categorize immunity in patients that uses a combination of whole blood flow cytometry and hierarchical clustering. Methods: Our approach was based on...
18.
Kumar S, Laplant B, Chng W, Zonder J, Callander N, Fonseca R, et al.
Blood
. 2014 Nov;
125(3):443-8.
PMID: 25395429
Dysregulation of cyclin-dependent kinases is a hallmark of myeloma, and specifically, cdk5 inhibition can enhance the activity of proteasome inhibitors in vitro. Dinaciclib is a novel potent small molecule inhibitor...
19.
Mattison R, Jumonville A, Flynn P, Moreno-Aspitia A, Erlichman C, Laplant B, et al.
Leuk Lymphoma
. 2014 Oct;
56(7):2061-6.
PMID: 25329007
Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism...
20.
Nowakowski G, Laplant B, Macon W, Reeder C, Foran J, Nelson G, et al.
J Clin Oncol
. 2014 Aug;
33(3):251-7.
PMID: 25135992
Purpose: Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone);...